Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991584
Published Content info 292 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 292 Pages
Description

Global pharmacogenetic testing in psychiatry/depression market is projected to register a substantial CAGR of 9.4% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation

Global Pharmacogenetic Testing In Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-The-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-To-Consumer Services and Mail-Order Pharmacies), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa, Brazil and Rest of South America) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of the pharmacogenetic testing in psychiatry/depression market are:

  • Rise in number of people suffering from major depressive disorders.
  • Technological advancement and increased healthcare expenditure.

Market Players

The key market players for the pharmacogenetic testing in psychiatry/depression market are listed below:

  • BiogeniQ Inc.
  • GenXys
  • Genomind, Inc.
  • Myriad Genetics, Inc.
  • AltheaDx
  • STADA Arzneimittel AG
  • Sonic Healthcare
  • ONEOME
  • Thermo Fisher Scientific Inc.
  • Millennium Health
  • Coriell Life Sciences
  • Healthspek
  • Color
  • GENELEX
  • OmeCare
  • AB-Biotics, S.A.
  • Luminex Corporation
  • Illumina, Inc.
  • PerkinElmer Inc.
  • HudsonAlpha Health Alliance (a division of HudsonAlpha)
  • Dynamic DNA Laboratories
  • cnsdose,
  • myDNA Life Australia Pty Ltd.
  • R-Biopharm AG
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET APPLICATION COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 REGULATIONS: GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

  • 5.1 UNITED STATES
    • 5.1.1 ROLE OF FDA
    • 5.1.2 ROLE OF CDC AND HCFA
  • 5.2 EUROPEAN UNION
  • 5.3 FRANCE
  • 5.4 AUSTRALIA
  • 5.5 SOUTH KOREA

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
    • 6.1.2 INITIATIVES TAKEN BY MANUFACTURERS
    • 6.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
    • 6.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
    • 6.1.5 GROWING MEDICAL TOURISM
  • 6.2 RESTRAINTS
    • 6.2.1 LACK OF STRONG CLINICAL EVIDENCE
    • 6.2.2 HIGH COST
    • 6.2.3 LACK OF REIMBURSEMENT
  • 6.3 OPPORTUNITIES
    • 6.3.1 TECHNOLOGICAL ADVANCEMENTS
    • 6.3.2 EMERGENCE OF NEW PLAYERS
    • 6.3.3 UNTAPPED MARKET
  • 6.4 CHALLENGES
    • 6.4.1 STRINGENT GOVERNMENT REGULATION
    • 6.4.2 SHORTAGE OF SKILLED PERSONNEL

7 COVID-19 IMPACT ON GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

  • 7.1 IMPACT ON PRICE
  • 7.2 IMPACT ON DEMAND
  • 7.3 IMPACT ON SUPPLY
  • 7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
  • 7.5 CONCLUSION:

8 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE

  • 8.1 OVERVIEW
  • 8.2 WHOLE GENOME SEQUENCING
  • 8.3 ARRAY-BASED TESTS

9 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES

  • 9.1 OVERVIEW
  • 9.2 CYP2C19
  • 9.3 CYP2C9 AND VKORC1
  • 9.4 CYP2D6
  • 9.5 HLA-B
  • 9.6 HTR2A/C
  • 9.7 HLA-A
  • 9.8 CYP3A4
  • 9.9 SLC6A4
  • 9.10 MTHFR
  • 9.11 COMT
  • 9.12 OTHERS

10 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE

  • 10.1 OVERVIEW
  • 10.2 PRESCRIPTION DRUGS
  • 10.3 OVER-THE-COUNTER MEDICATIONS
  • 10.4 RECREATIONAL DRUGS
  • 10.5 VITAMINS/NUTRACEUTICALS

11 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE

  • 11.1 OVERVIEW
  • 11.2 SALIVA
  • 11.3 BLOOD

12 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION

  • 12.1 OVERVIEW
  • 12.2 DRUG DEVELOPMENT
  • 12.3 CLINICAL PRACTICE

13 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 13.3 HEALTHCARE PROVIDERS
  • 13.4 RESEARCH CENTERS AND ACADEMIC INSTITUES
  • 13.5 OTHERS

14 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL

  • 14.1 OVERVIEW
  • 14.2 RETAIL PHARMACIES
  • 14.3 HOSPITAL PHARMACIES
  • 14.4 MAIL-ORDER PHARMACIES
  • 14.5 DIRECT-TO-CUSTOMER SERVICES

15 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GEOGRAPHY

  • 15.1 OVERVIEW
  • 15.2 NORTH AMERICA
    • 15.2.1 U.S.
    • 15.2.2 CANADA
    • 15.2.3 MEXICO
  • 15.3 EUROPE
    • 15.3.1 U.K.
    • 15.3.2 GERMANY
    • 15.3.3 FRANCE
    • 15.3.4 ITALY
    • 15.3.5 SPAIN
    • 15.3.6 NETHERLANDS
    • 15.3.7 BELGIUM
    • 15.3.8 RUSSIA
    • 15.3.9 SWITZERLAND
    • 15.3.10 TURKEY
    • 15.3.11 REST OF EUROPE
  • 15.4 ASIA-PACIFIC
    • 15.4.1 JAPAN
    • 15.4.2 CHINA
    • 15.4.3 SOUTH KOREA
    • 15.4.4 INDIA
    • 15.4.5 AUSTRALIA
    • 15.4.6 SINGAPORE
    • 15.4.7 THAILAND
    • 15.4.8 MALAYSIA
    • 15.4.9 INDONESIA
    • 15.4.10 PHILIPPINES
    • 15.4.11 REST OF ASIA-PACIFIC
  • 15.5 SOUTH AMERICA
    • 15.5.1 BRAZIL
    • 15.5.2 ARGENTINA
    • 15.5.3 REST OF SOUTH AMERICA
  • 15.6 MIDDLE EAST & AFRICA
    • 15.6.1 SOUTH AFRICA
    • 15.6.2 SAUDI ARABIA
    • 15.6.3 UAE
    • 15.6.4 ISRAEL
    • 15.6.5 EGYPT
    • 15.6.6 REST OF MIDDLE EAST & AFRICA

16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE

  • 16.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 16.3 COMPANY SHARE ANALYSIS: EUROPE
  • 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

  • 18.1 MYRIAD GENETICS, INC.
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 COMPANY SHARE ANALYSIS
    • 18.1.4 PRODUCT PORTFOLIO
    • 18.1.5 RECENT DEVELOPMENTS
  • 18.2 THERMO FISHER SCIENTIFIC INC.
    • 18.2.1 COMPANY SNAPSHOT
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 COMPANY SHARE ANALYSIS
    • 18.2.4 PRODUCT PORTFOLIO
    • 18.2.5 RECENT DEVELOPMENT
  • 18.3 STADA ARZNEIMITTEL AG
    • 18.3.1 COMPANY SNAPSHOT
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 COMPANY SHARE ANALYSIS
    • 18.3.4 PRODUCT PORTFOLIO
    • 18.3.5 RECENT DEVELOPMENTS
  • 18.4 SONIC HEALTHCARE
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 REVENUE ANALYSIS
    • 18.4.3 COMPANY SHARE ANALYSIS
    • 18.4.4 PRODUCT PORTFOLIO
    • 18.4.5 RECENT DEVELOPMENT
  • 18.5 ILLUMINA, INC.
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 COMPANY SHARE ANALYSIS
    • 18.5.4 PRODUCT PORTFOLIO
    • 18.5.5 RECENT DEVELOPMENTS
  • 18.6 AB-BIOTICS, S.A.
    • 18.6.1 COMPANY SNAPSHOT
    • 18.6.2 REVENUE ANALYSIS
    • 18.6.3 6.3 PRODUCT PORTFOLIO
    • 18.6.4 RECENT DEVELOPMENTS
  • 18.7 ALTHEADX
    • 18.7.1 COMPANY SNAPSHOT
    • 18.7.2 PRODUCT PORTFOLIO
    • 18.7.3 RECENT DEVELOPMENT
  • 18.8 BIOGENIQ INC.
    • 18.8.1 COMPANY SNAPSHOT
    • 18.8.2 PRODUCT PORTFOLIO
    • 18.8.3 RECENT DEVELOPMENT
  • 18.9 COLOR
    • 18.9.1 COMPANY SNAPSHOT
    • 18.9.2 PRODUCT PORTFOLIO
    • 18.9.3 RECENT DEVELOPMENTS
  • 18.10 CNSDOSE
    • 18.10.1 COMPANY SNAPSHOT
    • 18.10.2 PRODUCT PORTFOLIO
    • 18.10.3 RECENT DEVELOPMENT
  • 18.11 CORIELL LIFE SCIENCES
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 PRODUCT PORTFOLIO
    • 18.11.3 RECENT DEVELOPMENTS
  • 18.12 DYNAMIC DNA LABORATORIES
    • 18.12.1 COMPANY SNAPSHOT
    • 18.12.2 PRODUCT PORTFOLIO
    • 18.12.3 RECENT DEVELOPMENTS
  • 18.13 GENELEX
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 PRODUCT PORTFOLIO
    • 18.13.3 RECENT DEVELOPMENT
  • 18.14 GENOMIND, INC.
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 PRODUCT PORTFOLIO
    • 18.14.3 RECENT DEVELOPMENTS
  • 18.15 GENXYS
    • 18.15.1 COMPANY SNAPSHOT
    • 18.15.2 PRODUCT PORTFOLIO
    • 18.15.3 RECENT DEVELOPMENTS
  • 18.16 HEALTHSPEK
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 PRODUCT PORTFOLIO
    • 18.16.3 RECENT DEVELOPMENT
  • 18.17 HUDSONALPHA HEALTH ALLIANCE (A DIVISION OF HUDSONALPHA)
    • 18.17.1 COMPANY SNAPSHOT
    • 18.17.2 PRODUCT PORTFOLIO
    • 18.17.3 RECENT DEVELOPMENT
  • 18.18 LUMINEX CORPORATION
    • 18.18.1 COMPANY SNAPSHOT
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 PRODUCT PORTFOLIO
    • 18.18.4 RECENT DEVELOPMENTS
  • 18.19 MILLENNIUM HEALTH
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 PRODUCT PORTFOLIO
    • 18.19.3 RECENT DEVELOPMENTS
  • 18.20 MYDNA LIFE AUSTRALIA PTY LTD.
    • 18.20.1 COMPANY SNAPSHOT
    • 18.20.2 PRODUCT PORTFOLIO
    • 18.20.3 RECENT DEVELOPMENT
  • 18.21 ONEOME
    • 18.21.1 COMPANY SNAPSHOT
    • 18.21.2 PRODUCT PORTFOLIO
    • 18.21.3 RECENT DEVELOPMENTS
  • 18.22 OMECARE
    • 18.22.1 COMPANY SNAPSHOT
    • 18.22.2 PRODUCT PORTFOLIO
    • 18.22.3 RECENT DEVELOPMENT
  • 18.23 PERKINELMER INC.
    • 18.23.1 COMPANY SNAPSHOT
    • 18.23.2 REVENUE ANALYSIS
    • 18.23.3 PRODUCT PORTFOLIO
    • 18.23.4 RECENT DEVELOPMENTS
  • 18.24 R-BIOPHARM AG
    • 18.24.1 COMPANY SNAPSHOT
    • 18.24.2 PRODUCT PORTFOLIO
    • 18.24.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD MILLION)
  • TABLE 2 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 3 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 4 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD MILLION)
  • TABLE 5 GLOBAL CYP2C19 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 6 GLOBAL CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 7 GLOBAL CYP2D6 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 8 GLOBAL HLA-B IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 9 GLOBAL HTR2A/C IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 10 GLOBAL HLA-A IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 11 GLOBAL CYP3A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 GLOBAL SLC6A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 13 GLOBAL MTHFR IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 GLOBAL COMT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 15 GLOBAL OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD MILLION)
  • TABLE 17 GLOBAL PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 GLOBAL OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 19 GLOBAL RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 GLOBAL VITAMINS/NUTRACEUTICALS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD MILLION)
  • TABLE 22 GLOBAL SALIVA IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 23 GLOBAL BLOOD IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD MILLION)
  • TABLE 25 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 26 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD MILLION)
  • TABLE 28 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 GLOBAL HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 30 GLOBAL RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 31 GLOBAL OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD MILLION)
  • TABLE 33 GLOBAL RETAIL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 34 GLOBAL HOSPITAL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 35 GLOBAL MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION))
  • TABLE 36 GLOBAL DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 37 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET , BY REGION, 2021-2028 (USD MILLION)
  • TABLE 38 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 39 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 40 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 41 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 42 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 43 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 44 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 45 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 46 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 47 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 48 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 49 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 50 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 51 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 52 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 53 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 54 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 55 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 56 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 57 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 58 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 59 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 60 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 61 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 62 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 63 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 64 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 65 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 66 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 67 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 68 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 69 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 70 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 71 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 72 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 73 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 74 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 75 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 76 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 77 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 78 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 79 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 80 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 81 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 82 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 83 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 84 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 85 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 86 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 87 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 88 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 89 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 90 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 91 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 92 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 93 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 94 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 95 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 96 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 97 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 98 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 99 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 100 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 101 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 102 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 103 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 104 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 105 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 106 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 107 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 108 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 109 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 110 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 111 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 112 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 113 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 114 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 115 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 116 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 117 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 118 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 119 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 120 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 121 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 122 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 123 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 124 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 125 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 126 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 127 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 128 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 129 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 130 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 131 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 132 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 133 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 134 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 135 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 136 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 137 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 138 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 139 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 140 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 141 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 142 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 143 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 144 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 145 REST OF EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 146 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
  • TABLE 147 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 148 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 149 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 150 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 151 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 152 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 153 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 154 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 155 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 156 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 157 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 158 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 159 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 160 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 161 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 162 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 163 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 164 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 165 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 166 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 167 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 168 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 169 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 170 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 171 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 172 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 173 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 174 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 175 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 176 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 177 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 178 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 179 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 180 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 181 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 182 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 183 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 184 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 185 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 186 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 187 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 188 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 189 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 190 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 191 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 192 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 193 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 194 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 195 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 196 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 197 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 198 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 199 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 200 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 201 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 202 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 203 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 204 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 205 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 206 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 207 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 208 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 209 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 210 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 211 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 212 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 213 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 214 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 215 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 216 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 217 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 218 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 219 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 220 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 221 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 222 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 223 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 224 REST OF ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 225 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 226 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 227 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 228 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 229 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 230 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 231 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 232 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 233 BRAZIL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 234 BRAZIL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 235 BRAZIL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 236 BRAZIL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 237 BRAZIL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 238 BRAZIL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 239 BRAZIL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 240 ARGENTINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 241 ARGENTINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 242 ARGENTINA HARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 243 ARGENTINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 244 ARGENTINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 245 ARGENTINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 246 ARGENTINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 247 REST OF SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 248 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 249 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 250 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 251 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 252 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 253 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 254 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 255 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 256 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 257 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 258 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 259 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 260 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 261 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 262 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 263 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 264 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 265 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 266 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 267 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 268 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 269 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 270 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 271 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 272 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 273 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 274 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 275 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 276 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 277 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 278 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 279 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 280 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 281 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 282 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 283 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 284 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 285 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 286 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 287 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 288 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 289 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 290 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 291 REST OF MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
  • FIGURE 2 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DATA TRIANGULATION
  • FIGURE 3 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DROC ANALYSIS
  • FIGURE 4 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: MARKET APPLICATION COVERAGE GRID
  • FIGURE 9 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 10 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
  • FIGURE 11 INITIATIVES TAKEN BY MANUFACTURERS IS EXPECTED TO DRIVE THE GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN 2021 & 2028
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
  • FIGURE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028
  • FIGURE 17 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)
  • FIGURE 18 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)
  • FIGURE 19 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE
  • FIGURE 20 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028
  • FIGURE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)
  • FIGURE 22 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)
  • FIGURE 23 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE
  • FIGURE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028
  • FIGURE 25 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)
  • FIGURE 26 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
  • FIGURE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE
  • FIGURE 28 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028
  • FIGURE 29 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • FIGURE 30 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
  • FIGURE 31 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE
  • FIGURE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028
  • FIGURE 33 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
  • FIGURE 34 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)
  • FIGURE 35 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE
  • FIGURE 36 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028
  • FIGURE 37 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)
  • FIGURE 38 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)
  • FIGURE 39 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 40 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028
  • FIGURE 41 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • FIGURE 42 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
  • FIGURE 43 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 44 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 45 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY REGION (2020)
  • FIGURE 46 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY REGION (2021 & 2028)
  • FIGURE 47 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY REGION (2020 & 2028)
  • FIGURE 48 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 49 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 50 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
  • FIGURE 51 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 52 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 53 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 54 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 55 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
  • FIGURE 56 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 57 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 58 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 59 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 60 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
  • FIGURE 61 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 62 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 63 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 64 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 65 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
  • FIGURE 66 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 67 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 68 SOUTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 69 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 70 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
  • FIGURE 71 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 72 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 73 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 74 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2020 (%)
  • FIGURE 75 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2020 (%)
  • FIGURE 76 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2020 (%)
  • FIGURE 77 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2020 (%)
Back to Top